Achieve Life Sciences(NASDAQ) ACHV

Achieve Life Sciences, Inc. helps people quit smoking and vaping. Its main product reduces nicotine cravings and withdrawal symptoms. This company develops treatments for global nicotine dependence.

Fighting the Nicotine Habit

• Smoking Cessation: A plant-based drug candidate designed to help adults quit combustible cigarettes; no revenue generated to date.
• Vaping Cessation: An investigational treatment targeting nicotine e-cigarette use in both adults and adolescents.

Moving Toward Commercial Launch

• Partnered with Adare Pharma Solutions in 2026 to manage drug manufacturing and supply chain risks.
• Received the Commissioner's National Priority Voucher from the FDA in Oct. 2025 for vaping cessation.
• Completed the ORCA-OL clinical trial in Sept. 2025 to study the long-term safety of its lead candidate.
• Raised $168.2 million in net proceeds through a private placement financing in April 2026.

A Natural Path to Quitting

Achieve uses cytisinicline, a plant-based compound that targets specific brain receptors to lower nicotine satisfaction. This treatment offers flexible 6 or 12-week dosing schedules to improve patient success rates during the quitting process.

Numbers Behind the Science

• Net loss was $84.9 million for the six-month period ended June 30, 2026.
• Cash and marketable securities reached $187.3 million as of June 30, 2026.
• Research and development expenses were $7.1 million for the six months ended June 30, 2026.
• General and administrative costs totaled $21.8 million for the six-month period ended June 30, 2026.

The Evolution of Achieve

Achieve has shifted its focus toward commercial readiness while addressing regulatory manufacturing requirements. The company maintains a pipeline dedicated to solving the nicotine addiction crisis through clinical development and strategic manufacturing partnerships.